Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EV-100
- Development stage
- Preclinical
- Lead developer
- Evrys Bio
- Modality
- Small Molecules
01
Overview
EV-100 is a small molecule modulator of Sirtuin 2 (SIRT2) being developed by Evrys Bio as a host-targeted antiviral (HTA) therapy. SIRT2 is a member of the sirtuin family of NAD+-dependent deacetylases that plays a critical role in regulating host cell metabolism and protein function, which many viruses exploit for replication. By targeting a host protein rather than a viral protein, EV-100 aims to provide a broad-spectrum antiviral effect with a higher barrier to resistance. The program focuses on treating chronic infections like Hepatitis B Virus (HBV) and Human Cytomegalovirus (HCMV), as well as other viral pathogens. EV-100 is identified as a clinic-ready asset within Evrys Bio's sirtuin-modulation platform.
- Other names
- SIRT2 modulatorsSIRT-2 modulatorsSIRT 2 modulators
02
Targets
SIRT2 (NAD-dependent protein deacetylase sirtuin-2)
Beyond the preview
Go deeper on EV-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EV-100.